Genetic Changes in Patients With Non-Small Cell Lung Cancer Who Are Receiving Vinorelbine and Gemcitabine Before Surgery
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Determination of genetic changes in patients with non-small cell lung cancer may
help predict the outcome of treatment. Drugs used in chemotherapy use different ways to stop
tumor cells from dividing so they stop growing or die. Combining more than one drug, and
giving them before surgery, may shrink the tumor so that it can be removed during surgery.
PURPOSE: Phase II trial to study genetic changes and the effectiveness of combining
vinorelbine with gemcitabine before surgery in treating patients who have stage IB, stage II,
or stage III non-small cell lung cancer.